Last reviewed · How we verify
Ricover-scheme rituximab
Ricover-scheme rituximab is a Monoclonal antibody (anti-CD20) Small molecule drug developed by Universität des Saarlandes. It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen), Diffuse large B-cell lymphoma (DLBCL).
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduced antibody production in lymphoma and autoimmune conditions.
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduced antibody production in lymphoma and autoimmune conditions. Used for B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen), Diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | Ricover-scheme rituximab |
|---|---|
| Sponsor | Universität des Saarlandes |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The R-CHOP/Ricover scheme combines rituximab with chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to enhance anti-tumor efficacy in B-cell malignancies.
Approved indications
- B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen)
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Infusion reactions
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea/vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ricover-scheme rituximab CI brief — competitive landscape report
- Ricover-scheme rituximab updates RSS · CI watch RSS
- Universität des Saarlandes portfolio CI
Frequently asked questions about Ricover-scheme rituximab
What is Ricover-scheme rituximab?
How does Ricover-scheme rituximab work?
What is Ricover-scheme rituximab used for?
Who makes Ricover-scheme rituximab?
What drug class is Ricover-scheme rituximab in?
What development phase is Ricover-scheme rituximab in?
What are the side effects of Ricover-scheme rituximab?
What does Ricover-scheme rituximab target?
Related
- Drug class: All Monoclonal antibody (anti-CD20) drugs
- Target: All drugs targeting CD20
- Manufacturer: Universität des Saarlandes — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen)
- Indication: Drugs for Diffuse large B-cell lymphoma (DLBCL)
- Compare: Ricover-scheme rituximab vs similar drugs
- Pricing: Ricover-scheme rituximab cost, discount & access